In a longer-term context, Regeneron's total shareholder return, including dividends, was a decline of 8.37% over the past five years. This performance trails the past year's market return of 8% and ...

Some research has shown that dividend-paying stocks significantly outperformed their non-dividend-paying peers over the past ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Representative Robert Bresnahan Jr. recently waved goodbye to his Regeneron Pharmaceuticals shares, sparking curiosity over ...

Humankind Investments increased its stake in Regeneron Pharmaceuticals by 62.3%, showing rising investor interest despite the ...

Regeneron (REGN) stock was upgraded to Buy and AbbVie (ABBV) stock was downgraded at Citi based on policy risks under Trump's drug reforms. Read more here.

Regeneron Pharmaceuticals Up Nearly 7%, On Pace For Largest Percent Increase Since September 2022 — Data Talk Regeneron Pharmaceuticals, Inc. (REGN) is currently at $568.11, up $40.33 or 7.64% --On ...

Sanofi plans $20 billion US investment by 2030 to expand R&D and manufacturing, aiming to boost medicine production and job ...

Real-time index price for TSX Composite High Dividend Index (TXEI), along with buy or sell indicators, analysis, charts, historical performance, news and more ...

Regeneron anticipates a decline in EYLEA sales due to biosimilar competition. DUPIXENT continues to expand globally, with significant growth expected by 2030. The company is investing $7 billion ...